NIH #1R01CA307511-01
Intratumor Heterogeneity as a Correlate of Clinical Outcome in Patients Avoiding Radical Cystectomy
- Amount
- $766K
- Period
- 2026-04-01 → 2031-03-31
- PIs
- 2
- Est. capacity / PI
- ~6 students
Awarded at RESEARCH INST OF FOX CHASE CAN CTR
Bladder and Urothelial Cancer Treatments · Surgery
1 total · 1 active
NIH #1R01CA307511-01
Awarded at RESEARCH INST OF FOX CHASE CAN CTR
Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.
Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.
Science Advances · 2026-06-26
The Journal of Experimental Medicine · 2026-04-29
npj Precision Oncology · 2026-04-18
2025-11-24
2025-11-24
2025-11-24
APOBEC3A-Induced DNA Damage Drives Polymerase θ Dependency and Synthetic Lethality in CancerPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2025-10-22 · 1 citations
HER2 and urothelial carcinoma: current understanding and future directions
Nature Reviews Urology · 2025-08-15 · 17 citations
bioRxiv (Cold Spring Harbor Laboratory) · 2025-08-14 · 2 citations
International Society of Urological Pathology Consensus Meeting 2024
The American Journal of Surgical Pathology · 2025-07-01 · 3 citations
2025-06-03
2025-06-03
2025-06-03
Journal of Clinical Oncology · 2025-05-28 · 4 citations
Cancer Research · 2025-04-25
Cancer Research · 2025-04-21
Pan-Cancer PDOs Preserve Tumor Heterogeneity and Uncover Therapeutic VulnerabilitiesPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2025-04-17
Nature Methods · 2025-04-11 · 15 citations
Cancer Discovery · 2025-03-07 · 21 citations
INTRAVESICAL MUC16 TARGETING CAR T CELLS FOR ORGAN-CONFINED BLADDER CANCERS
Urologic Oncology Seminars and Original Investigations · 2025-02-27 · 1 citations